X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

Discover how Moleculin Biotech advances Annamycin's Phase 3 trial for AML treatment, with key milestones planned through 2025.

There is a growing opportunity to expand clinical research capacity in Africa, and numerous organisations are contributing to this effort. To name a few: the African Medicines Agency provides ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

An even greater challenge is their need for external investment. During the early stages of development, in order to progress ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

This Perspective outlines evidence on existing platform trials in mental health and discusses key challenges and strategies to overcome barriers in order to maximize the potential of platform trials.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy. The first patient has been enrolled in the phase ...

Kodiak Sciences has completed enrollment in its GLOW2 phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy (DR). GLOW2 (NCT06270836) is a prospective, randomized, double ...

Kodiak Sciences (KOD) announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy. “We randomized more than 250 ...